Alopecia

Despite the increased incidence of common and viral infections in individuals with AA, this study found no clinically significant association between AA and increased risk for infections. Alopecia areata (AA) is a prevalent autoimmune disorder that commonly occurs during early adulthood. Previous studies have highlighted a complex association between autoimmunity and infections. This population-based cohort...

Baricitinib is safe and effective for the treatment of severe alopecia areata as compared to placebo in two phase 3 randomized controlled trials. Alopecia areata (AA) is an autoimmune condition that causes hair loss in different areas of the body, including eyelashes, scalp, and eyebrows. The treatment modalities for AA are limited. Baricitinib is an...

The therapeutic efficacy of Jessner solution is comparable to an injectable intralesional steroid for improving multifocal patchy alopecia areata. Alopecia areata (AA) is referred to as an autoimmune disorder characterized by non-scarring loss of hair. Despite the associated health burden, there is no definitive cure for this disorder. This study, published in the Journal of...

Dermatologist Dr. Edidiong Kaminska, MD, has been in medicine for more than 13 years and practices in Chicago, Illinois. Dr. Kaminska has a wealth of knowledge on skin conditions. We discuss the topic of racial disparities among patients with alopecia areata. She gave a bit of background on the disease, the history, and treatment, and...

In this interview, we speak with Dr. Kaminska about Olumiant about a novel treatment for alopecia. In addition to explaining what it is and why it can be a good option for certain patients, Dr. Kaminska provides a fair assessment of its effectiveness and safety. MDNewsline: What is the efficacy and safety of Olumiant in...

There is an association between the development/exacerbation of AA and SARS-CoV-2 infection. However, more studies are required to evaluate this association and contribute to improvement in the dermatological and psychological outcomes in patients with COVID-19. COVID-19 is a viral SARS-CoV-2 infection associated with several immune-related dermatological conditions. Alopecia areata (AA) is an autoimmune disease with...

A recent systematic review assessed different treatment modalities for pediatric Alopecia areata (AA). Topical corticosteroids are the first-line treatment of AA in children. Alopecia areata (AA) is an auto-immune disorder that involves non-scarring hair loss. AA has a slightly greater prevalence in the pediatric population than in adults. Approximately 80% of individuals with patchy limited...

The treatment of AA with brepocitinib and ritlecitinib is associated with a reduction in the SALT scores. This is also related to the downregulation of TH1 cells and the upregulation of hair keratins. Future clinical trials are required to assess the safety, efficacy, dosage, and duration of treatment with JAK inhibitors. Alopecia areata (AA) is...

A group of 22 US board-certified dermatologists have endorsed the alopecia areata (AA) disease severity scale. The scale assesses the extent of hair loss on the scalp, hair loss in the special hair-bearing sites, previous treatment response, psychological impact, and diffuse and rapid hair loss to evaluate the severity of AA. Alopecia areata (AA) is...